Can Fetal Growth Velocity and First Trimester Maternal Biomarkers Improve the Prediction of Small-for-Gestational Age and Adverse Neonatal Outcome?
Open Access
- 8 May 2019
- journal article
- research article
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 46 (4) , 274-284
Abstract
Background and Objectives: The aim of this study was to evaluate the value of adding fetal growth velocity and first trimester maternal biomarkers to baseline screening, for the prediction of small-for-gestational age (SGA) and adverse neonatal outcomes. Method: A retrospective cohort study was conducted of singleton pregnancies in the Maastricht University Medical Centre between 2012 and 2016. The biomarkers PAPP-A, β-hCG, PlGF, and sFlt-1 were measured at 11–13 weeks of gestational age (GA) and two fetal growth scans were performed (18–22 and 30–34 weeks of GA). Differences in biomarkers and growth velocities were compared between appropriate-for-gestational age (AGA; birth weight percentile 10–90) and SGA (birth weight percentile Results: We included 296 singleton pregnancies. Compared to AGA (n = 251), SGA neonates (n = 45) had significantly lower growth velocities in the abdominal circumference (mm/week): 10.1 ± 0.98 versus 10.8 ± 0.98, p = 0.001. Compared with AGA, the SGA neonates had higher sFlt-1 multiples of the median (MoM): 0.89 (0.55) versus 0.76 (0.44), p = 0.023, and a higher sFlt-1/PlGF MoM ratio: 1.09 (1.03) versus 0.90 (0.64), p = 0.027. For a 15% false-positive rate, the prediction of SGA neonates increased from 44.8% for the baseline screening model to 56.5% after the addition of fetal growth velocities, and to 73.9% after the further addition of maternal biomarkers (PPV 9.6%, NPV 82.4%). The corresponding AUC for the three models were 0.722, 0.804, and 0.839, respectively. In addition, AGA neonates with reduced fetal growth velocity had more adverse neonatal outcomes compared to the AGA reference group (12.4 vs. 3.9%, p = 0.013). Conclusions: Combining fetal growth velocity with first trimester biomarkers resulted in a better prediction of SGA compared to baseline screening parameters alone. This approach could possibly result in reduced adverse neonatal outcomes in neonates, who are at a potential risk due to late mild placental dysfunction.Keywords
This publication has 52 references indexed in Scilit:
- Combined screening for early and late pre-eclampsia and intrauterine growth restriction by maternal history, uterine artery Doppler, mean arterial pressure and biochemical markersAdvances in Clinical and Experimental Medicine, 2017
- Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational studyObstetrics & Gynecology Science, 2017
- Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort studyThe Lancet, 2015
- An integrated model with classification criteria to predict small‐for‐gestational‐age fetuses at risk of adverse perinatal outcomeUltrasound in Obstetrics & Gynecology, 2014
- First trimester screening for intra‐uterine growth restriction and early‐onset pre‐eclampsiaPrenatal Diagnosis, 2011
- Pathophysiology of perinatal asphyxia: can we predict and improve individual outcomes?EPMA Journal, 2011
- First‐trimester placental growth factor as a marker for hypertensive disorders and SGAPrenatal Diagnosis, 2010
- Intrauterine Growth Restriction as a Potential Risk Factor for Disease Onset in AdulthoodJournal of Pediatric Endocrinology and Metabolism, 2010
- Perinatal Outcome and Later Implications of Intrauterine Growth RestrictionClinical Obstetrics and Gynecology, 2006
- [Intrauterine growth and intrauterine growth curves].1969